NasdaqCM - Delayed Quote USD

CERo Therapeutics Holdings, Inc. (CEROW)

0.0099
0.0000
(0.00%)
At close: June 10 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Christopher B. Ehrlich M.B.A. CEO & Chair 1.08M -- 1970
Mr. Andrew Albert Kucharchuk M.B.A. Chief Financial Officer 252k -- 1981
Dr. Kristen Pierce Ph.D. Chief Development Officer 360k -- 1971
Dr. Lawrence Corey M.D. Co-founder & Head of Scientific Advisory Board -- -- 1947

CERo Therapeutics Holdings, Inc.

201 Haskins Way
Suite 230
South San Francisco, CA 94080
United States
(650) 407-2376 https://www.cero.bio
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
8

Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Corporate Governance

CERo Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers